Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence

Bottom line

• Lokivetmab (Cytopoint) is a caninized anti-interleukin-31 monoclonal antibody (IgG4-kappa) that neutralizes free IL-31 — the primary pruritogenic cytokine in canine atopic dermatitis (AD) — delivering targeted itch control without systemic immunosuppression or JAK-STAT inhibition [1].
• Two pivotal blinded, randomized, placebo-controlled RCTs established efficacy and safety: single subcutaneous doses of 0.5 and 2.0 mg/kg reduced pruritus versus placebo for at least one month, with onset typically within 24–48 hours; the 0.125 mg/kg dose was not effective [1][2].
• Durability is now well characterized. As of July 2026, a 12-month prospective cohort (Gober 2025, n=75) found 87% of dogs kept pruritus below their Day 0 baseline throughout treatment with no tachyphylaxis; a separate 75-dog long-term field study (Kasper 2024) reported a 72% treatment-success rate under real-world conditions [3][4].
• Lokivetmab was non-inferior to ciclosporin on pruritus at 16 weeks with faster onset and fewer GI adverse events (Moyaert 2017) [5]; lesion-score gains can lag ciclosporin's, consistent with IL-31's dominant role in itch versus chronic-lesion inflammation [8].
• For dogs failing both oclacitinib and lokivetmab as monotherapies, combination oclacitinib–lokivetmab therapy (COLT) achieved adequate pruritus control in 61% (27/44) with no observed adverse effects (Bachtel & Snidow 2026) [6].
• Safety is favorable across the evidence base: no immediate hypersensitivity reactions in the safety RCT, injection discomfort in ~5% (no different from placebo), and treatment-induced anti-drug antibodies in 2.5% of dogs — the only recognized efficacy-limiting immunogenicity signal [2].

Drug facts

• Class: Caninized anti-canine IL-31 monoclonal antibody (IgG4-kappa isotype); a biological, not a small molecule.
• Mechanism: Binds and sequesters soluble canine IL-31, preventing engagement of the IL-31RA/OSMRβ receptor complex on sensory neurons and keratinocytes; interrupts the itch–scratch cycle upstream of JAK signaling. Because it acts extracellularly on a single cytokine, it does not inhibit intracellular JAK-STAT pathways [1][2].
• Route/dose/interval: Subcutaneous injection, minimum 2 mg/kg; repeat every 4–8 weeks as needed based on individual owner-reported pruritus. Monthly re-injection is the label-approved default.
• Indication: Control of pruritus associated with allergic/atopic dermatitis in dogs (FDA NADA 141-514; EMA authorized as Cytopoint).
• Approval status: FDA full approval; EMA authorized; available in most major markets.
• Contraindications: None listed on label; use caution in dogs with known hypersensitivity to the product.
• Common adverse events: Injection-site discomfort (~5%, similar to placebo); lethargy and gastrointestinal signs reported rarely in post-market data. No metabolic CYP450-mediated drug interactions are expected because monoclonal antibodies are catabolized to amino acids, not hepatically metabolized (cytokine-mediated effects on CYP expression remain theoretically possible) [2].
• Immunogenicity: Treatment-induced anti-drug antibodies in 2.5% (4/162) of dogs in the safety RCT; affected dogs had day-28/42 serum lokivetmab concentrations ~90% lower than non-immunogenic dogs, correlating with reduced efficacy [2].

Efficacy: what the pivotal trials established

Lokivetmab was evaluated in two companion pivotal blinded, randomized, placebo-controlled trials by Michels et al. (2016), both in Veterinary Dermatology. The dose-determination trial [1] randomized client-owned atopic dogs to a single subcutaneous injection of lokivetmab at 0.125, 0.5, or 2.0 mg/kg or placebo, following pruritus for 56 days. It established a dose-response relationship: the 0.5 and 2.0 mg/kg doses reduced pruritus versus placebo for at least one month, while 0.125 mg/kg was not significantly effective; level and duration of response rose with dose. The companion safety trial [2] confirmed safety at the selected dose in a blinded, randomized, placebo-controlled design (245 enrolled; 162 lokivetmab-treated), reporting no immediate hypersensitivity reactions, injection discomfort in 5.1% (comparable to placebo), and 2.5% treatment-induced immunogenicity. Both trials used the pruritus Visual Analog Scale (pVAS/PVAS) as the primary instrument, with CADESI (Canine Atopic Dermatitis Extent and Severity Index) as a secondary lesion measure. In the dose-determination cohort, Day-28 treatment success was 57% — the short-term benchmark against which later long-term data are read.

Comparators: lokivetmab versus ciclosporin and versus saline

Versus ciclosporin (Moyaert 2017) [5]. A blinded, randomized clinical trial randomized 274 dogs with chronic AD to monthly injectable lokivetmab or oral ciclosporin for three months. Lokivetmab was non-inferior to ciclosporin on pruritus at 16 weeks, with a faster onset at Day 14 and fewer gastrointestinal adverse events than the ciclosporin arm. This trial positioned lokivetmab as a practical alternative to systemic calcineurin inhibition, with no required pre-treatment laboratory screening. A mechanistic caveat carried by the ICADA pathogenesis literature [8] is that chronic AD lesions recruit Th1/Th22 cytokines beyond the Th2/IL-31 axis, which can make lokivetmab's itch-focused mechanism produce comparatively less robust lesion-score improvement than ciclosporin's broader T-cell modulation — a distinction worth setting owner expectations around when visible skin disease, not just pruritus, is the primary complaint.

Versus saline in the field (Van Brussel 2021) [7]. A masked, randomized field trial across multiple European practices compared lokivetmab to saline control in client-owned dogs with allergic dermatitis, with PVAS and CADESI-4 at Days 14 and 28. Lokivetmab produced statistically significant and clinically meaningful reductions in both pruritus and skin-lesion scores at both time points, confirming efficacy in a diverse real-world population.

Durability: two independent long-term datasets

The pivotal trials were built around a 28-day endpoint, so real-world durability comes from two separate 75-dog studies that examine the year-long, repeat-injection pattern used in practice. They are complementary, not duplicative, and are reported here once each.

Gober et al. 2025 — 12-month prospective cohort [3]. Published in BMC Veterinary Research, this study followed 75 dogs at US-label dosing (every 4–8 weeks as needed) with assessments through Day 180 and Day 365. As of the 12-month readout:

• 87% (64/75) maintained PVAS below their own Day 0 baseline at every assessment — a deliberately strict criterion (a single visit above baseline disqualifies a dog), making 87% a conservative durability estimate with no evidence of tachyphylaxis.
• 88% (65/75) maintained a mean biweekly PVAS below 36 mm (the threshold for adequate control).
• 31% (23/75) held PVAS below 36 mm for the entire study; 11% (8/75) held PVAS below 20 mm (normal itch level) throughout.
• Owner satisfaction was 93% (64/69) at month 6 and 86% (59/69) at month 12; 86% planned to continue therapy and 80% reported being able to reduce concurrent medications. The modest month-6-to-12 satisfaction decline is plausibly attributable to seasonal allergen fluctuation or natural disease progression rather than drug failure. The study was sponsored by Zoetis.

Kasper et al. 2024 — long-term retrospective field study [4]. Published in Veterinary Dermatology (35(6):683–693), this independent analysis reviewed records from 75 client-owned atopic dogs receiving at least three consecutive lokivetmab injections. Treatment success (PVAS decrease ≥2 points, or post-treatment PVAS ≤2) was 72% across the cohort. Increasing treatment duration was associated with improved outcomes in a subset of dogs — a pattern not predictable from single-injection trial data. Response was attenuated in dogs with uncontrolled secondary infections and by higher baseline disease severity; the adverse-event profile mirrored the original RCTs (infrequent, mild, self-limiting; no new safety signals).

Synthesis. Read together, Gober's 87%-below-baseline durability metric and Kasper's 72% real-world success rate frame the same clinical reality from two angles: sustained pruritus benefit is the norm over a full year, but roughly a quarter to a third of dogs will need optimization — most often control of secondary pyoderma/Malassezia — to reach adequate control. Non-response is not infrequent, and the strictness of each study's endpoint matters when quoting numbers to colleagues or clients.

Multimodal therapy: combination with oclacitinib (COLT)

Bachtel & Snidow 2026 [6] (Veterinary Dermatology 37(2):287–292; PMID 41189387) is the first dedicated retrospective study of combination oclacitinib–lokivetmab therapy (COLT) in a refractory population: 44 client-owned dogs that had failed both oclacitinib and lokivetmab as separate monotherapies before being transitioned to concurrent oral oclacitinib plus subcutaneous lokivetmab.

• 61.4% (27/44) achieved adequate response (≥2 cm pVAS reduction plus clinician/owner consensus).
• In responders, mean pVAS fell from 6.87 to 2.67 out of 10 (61.1% decrease; p < 0.0001).
• No adverse effects attributable to the combination were identified.

Mechanistic rationale. The two agents hit distinct, complementary nodes of the atopic itch cascade. Lokivetmab neutralizes IL-31 extracellularly; oclacitinib inhibits JAK1, suppressing downstream signaling through multiple receptors (IL-31RA, IL-4R, IL-13R). Incomplete IL-31 blockade by the antibody may be rescued by downstream JAK1 inhibition, while dogs failing oclacitinib may retain IL-31-driven itch that direct neutralization captures. Their non-overlapping safety profiles (lokivetmab's very low AE burden; oclacitinib's demodicosis/papillomavirus susceptibility) argue against additive toxicity. A 2025 systematic review of anti-cytokine drugs in canine AD (International Journal of Molecular Sciences) likewise described COLT as a rational strategy for refractory disease, citing mechanistic complementarity and the absence of class-level safety concerns from pairing a JAK inhibitor with a cytokine-neutralizing antibody [9].

Interpretation. A 61% response in dogs who had already failed two agents is clinically meaningful but still leaves ~39% inadequately controlled, and the single-center retrospective design limits generalizability and cannot capture early dropouts (a possible tolerability bias). Document independent failure of each agent before combining.

The expanding JAK-inhibitor landscape (context for treatment selection)

Lokivetmab now sits alongside a widened set of oral JAK inhibitors that change the "what next" conversation after incomplete response. As of July 2026:

• Ilunocitinib (Zenrelia; Elanco) — FDA-approved September 2024 for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs ≥1 year; EU-approved July 2025. A non-selective, once-daily oral JAK inhibitor; a head-to-head RCT in 338 dogs across 25 sites and 4 countries demonstrated non-inferiority to oclacitinib at Day 28. It carries a boxed warning: no vaccination within 28 days before or after treatment, following fatal vaccine-induced disease and inadequate vaccine responses in a co-administration study [10].
• Atinvicitinib (Numelvi; Merck/MSD Animal Health) — EU-approved July 24, 2025; the first second-generation, JAK1-selective inhibitor in veterinary medicine (≥10-fold selectivity over JAK2/JAK3/TYK2), approved for dogs ≥6 months. It allows an adequate serological response to vaccination and has no known drug interactions — a clinically meaningful differentiator from ilunocitinib [11].

The 2015 ICADA treatment guidelines [12] remain the most recent comprehensive treatment-guideline document; the ICADA 2023 pathogenesis review series [13] provides updated mechanistic context (barrier dysfunction, microbiome dysbiosis, cytokine signaling) that, together with its cytokine review [8], reaffirms IL-31's "consistently strong central role" in canine AD pruritus and, by extension, the rationale for IL-31 neutralization as a durable target.

Contraindications, precautions & PK

• Contraindications: None on label. Avoid in dogs with prior hypersensitivity to lokivetmab.
• Immunogenicity as the main efficacy caveat: 2.5% of dogs develop treatment-induced anti-drug antibodies associated with ~90% lower serum drug levels and reduced response [2]; consider immunogenicity in a previously responsive dog that loses control despite appropriate intervals.
• Pharmacokinetics / interactions: As a monoclonal antibody, lokivetmab is cleared by proteolytic catabolism, not CYP450 metabolism, so classical metabolic drug–drug interactions are not expected; the safety trial deliberately permitted broad concomitant medication with no clinically apparent adverse interactions [2]. It is therefore compatible with antimicrobials, antiparasiticides, and short-course anti-inflammatories used during flare workups.
• Onset/offset: Onset typically 24–48 hours; effect duration generally 4–8 weeks, individualized by owner-reported pruritus.
• Population notes: No mandatory pre-treatment bloodwork (unlike ciclosporin). No CBC/chemistry monitoring is required by label, though secondary-infection control is essential to realize full benefit.

Practical decision support

• When lokivetmab is a strong first choice: owner preference for a monthly-to-bimonthly injectable over daily oral dosing; need for rapid flare control (24–48 h onset) during diagnostic workup; patients where daily oral compliance is unreliable; cases where avoiding routine lab monitoring is desirable.
• Set lesion expectations: if visible skin disease dominates the presentation, counsel that lesion-score improvement may trail pruritus relief and lag ciclosporin's broader effect [5][8]; pair with topical/antimicrobial therapy for secondary infection.
• Optimize before declaring failure: confirm secondary pyoderma/Malassezia is controlled and reassess interval timing; Kasper's data show infection control and adequate duration materially affect response [4].
• If considering COLT: document independent, adequately-dosed trials of oclacitinib (0.4–0.6 mg/kg BID ×30 days before stepping to once daily) and lokivetmab (weight-based, every 4–8 weeks) before combining; record a baseline pVAS/PVAS and reassess at 6–8 weeks; inform owners COLT is off-label with a single 44-dog evidence base; continue demodicosis surveillance on oclacitinib (no additional monitoring is added by lokivetmab) [6].
• If lokivetmab is inadequate: alternatives include ciclosporin, allergen-specific immunotherapy, short-course corticosteroids, or an oral JAK inhibitor — where vaccination schedule is a live consideration, atinvicitinib's vaccine compatibility contrasts with ilunocitinib's boxed vaccination warning [10][11].
• Interval management for cost: the once-monthly label interval is the default; some dogs with milder disease or lower baseline IL-31 may sustain control at 6–8 weeks, but no randomized extended-interval data exist — track individual PVAS trajectories to guide timing rather than extending empirically [3].

Frequently Asked Questions

How quickly does lokivetmab work in dogs with atopic dermatitis? Pivotal RCT data show pruritus reductions typically within 24–48 hours of subcutaneous injection, which makes it useful for acute flare control while a longer-term plan is worked up [1][2].

How long does a lokivetmab injection last, and does it lose effect over time? The label interval is every 4–8 weeks. Across a 12-month prospective cohort (Gober 2025), 87% of dogs kept pruritus below baseline at every visit and 88% maintained adequate control, with no evidence of tachyphylaxis; a separate long-term field study reported 72% treatment success [3][4].

Can lokivetmab be combined with oclacitinib? Yes. In dogs that had failed each drug as monotherapy, combination therapy (COLT) achieved adequate pruritus control in 61% (27/44), with a 61% mean pVAS reduction in responders and no observed adverse effects — though this rests on a single 44-dog retrospective study and is off-label (Bachtel & Snidow 2026) [6].

How does lokivetmab differ mechanistically from oclacitinib? Lokivetmab is a monoclonal antibody that neutralizes the soluble cytokine IL-31 directly, outside the cell; oclacitinib is a small-molecule JAK1 inhibitor that blocks intracellular signaling downstream of multiple cytokine receptors. Both target canine AD pruritus but at different points in the cascade [1][2].

Is lokivetmab safe for long-term use? Yes. The safety RCT reported no immediate hypersensitivity reactions and injection discomfort no different from placebo, and long-term data (Gober 2025, Kasper 2024) identified no new safety signals at label dosing [2][3][4].

How does lokivetmab compare to ciclosporin? In a randomized trial of 274 dogs, lokivetmab was non-inferior to ciclosporin on pruritus at 16 weeks with faster onset and fewer GI adverse events; lesion-score improvement may be comparatively less because IL-31 blockade targets itch rather than the full chronic-lesion inflammatory profile (Moyaert 2017) [5][8].

What is the immunogenicity risk with lokivetmab? Treatment-induced anti-drug antibodies occurred in 2.5% (4/162) of dogs in the safety RCT; those dogs had roughly 90% lower serum lokivetmab concentrations, which can reduce efficacy — a consideration in a previously responsive dog that loses control [2].

When should I reach for a newer JAK inhibitor instead? For incomplete lokivetmab response where daily oral therapy is acceptable, ilunocitinib (Zenrelia) and atinvicitinib (Numelvi) are options; note ilunocitinib's boxed warning against vaccination within 28 days of dosing versus atinvicitinib's documented vaccine compatibility and JAK1 selectivity [10][11].

Changelog

• 2026-07-06: Consolidated the lokivetmab evidence cluster into this evergreen hub. Folded in four dated dispatch posts: the 12-month durability cohort (Gober 2025), a second long-term durability dispatch (same Gober cohort — merged once, not duplicated), the long-term real-world field study (Kasper 2024, 72% success) with the ICADA 2023 pathogenesis update and the 2024–2025 JAK-inhibitor approvals (ilunocitinib, atinvicitinib), and the COLT combination-therapy retrospective (Bachtel & Snidow 2026). Corrected two citation errors carried by the dispatch posts: the Gober study's journal (BMC Veterinary Research, not Veterinary Dermatology) and the Kasper first-author initial (Bettina Kasper, "B", not "L"). All load-bearing citations re-verified against PubMed/DOI.
• 2026-06-09: First published.